Nephrotoxicity and Efficacy Assessment of Polymyxin B Use in Renal Transplant Patients

References

• Vattimo Mde F, Watanabe M, da Fonseca CD, Neiva LB, Pessoa EA, Borges FT. Polymyxin B nephrotoxicity: from organ to cell damage. PLoS One. 2016;11(8):e0161057. doi:10.1371/journal.pone.0161057
   PubMed Web of Science ®Google Scholar
• Mohapatra SS, Dwibedy SK, Padhy I. Polymyxins, the last-resort antibiotics: mode of action, resistance emergence, and potential solutions. J Biosci. 2021;46(3):46.
   Web of Science ®Google Scholar
• Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59(1):88–94. doi:10.1093/cid/ciu213
   PubMed Web of Science ®Google Scholar
• Sisay M, Hagos B, Edessa D, Tadiwos Y, Mekuria A. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res. 2020;163:105328. doi:10.1016/j.phrs.2020.105328
   Web of Science ®Google Scholar
• Kelesidis T, Falagas ME. The safety of polymyxin antibiotics. Expert Opin Drug Saf. 2015;14(11):1687–1701. doi:10.1517/14740338.2015.1088520
   PubMed Web of Science ®Google Scholar
• Wang P, Zhang Q, Zhu Z, et al. Comparing the population pharmacokinetics of and acute kidney injury due to Polymyxin B in Chinese patients with or without renal insufficiency. Antimicrob Agents Chemother. 2021;65(2). doi:10.1128/AAC.01900-20
   Web of Science ®Google Scholar
• Han L, Xu FM, Zhang XS, et al. Trough polymyxin B plasma concentration is an independent risk factor for its nephrotoxicity. Br J Clin Pharmacol. 2021. doi:10.1111/bcp.15061
   Web of Science ®Google Scholar
• Li Y, Deng Y, Zhu ZY, et al. Population pharmacokinetics of Polymyxin B and dosage optimization in renal transplant patients. Front Pharmacol. 2021;12:727170. doi:10.3389/fphar.2021.727170
   PubMed Web of Science ®Google Scholar
• Mostardeiro MM, Pereira CA, Marra AR, Pestana JO, Camargo LF. Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients. Antimicrob Agents Chemother. 2013;57(3):1442–1446. doi:10.1128/AAC.01329-12
   Web of Science ®Google Scholar
• Novelli G, Morabito V, Ferretti G, et al. Safety of polymyxin-B-based hemoperfusion in kidney and liver transplant recipients. Transplant Proc. 2012;44(7):1966–1972. doi:10.1016/j.transproceed.2012.05.057
   Web of Science ®Google Scholar
• Kaplan B, Meier-Kriesche HU. Renal transplantation: a half century of success and the long road ahead. J Am Soc Nephrol. 2004;15(12):3270–3271. doi:10.1097/01.ASN.0000146569.59482.8C
   Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39. doi:10.1002/phar.2209
   PubMed Web of Science ®Google Scholar
• Kdigo KD, Outcomes IG. Acute Kidney Injury Work Group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–138.
   Google Scholar
• Gibson GA, Bauer SR, Neuner EA, Bass SN, Lam SW. Influence of colistin dose on global cure in patients with bacteremia due to carbapenem-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2016;60(1):431–436. doi:10.1128/AAC.01414-15
   PubMed Web of Science ®Google Scholar
• Zhang J, Hu Y, Shen X, Zhu X, Chen J, Dai H. Risk factors for nephrotoxicity associated with polymyxin B therapy in Chinese patients. Int J Clin Pharm. 2021;43(4):1109–1115. doi:10.1007/s11096-020-01225-8
   Web of Science ®Google Scholar
• Cai Y, Leck H, Tan RW, et al. Clinical experience with high-dose Polymyxin B against carbapenem-resistant gram-negative bacterial Infections-A cohort study. Antibiotics. 2020;9(8). doi:10.3390/antibiotics9080451
   Web of Science ®Google Scholar
• Nation RL, Rigatto MHP, Falci DR, Zavascki AP. Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity. Antibiotics. 2019;8(1). doi:10.3390/antibiotics8010024
   Web of Science ®Google Scholar
• Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015;70(6):1903–1907. doi:10.1093/jac/dkv014
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Behle TF, Falci DR, et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother. 2015;70(5):1552–1557. doi:10.1093/jac/dku561
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients. Infect Drug Resist. 2017;10:293–298. doi:10.2147/IDR.S144314
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Oliveira MS, Perdigao-Neto LV, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus Polymyxin B. Antimicrob Agents Chemother. 2016;60(4):2443–2449. doi:10.1128/AAC.02634-15
   PubMed Web of Science ®Google Scholar
• John JF, Falci DR, Rigatto MH, Oliveira RD, Kremer TG, Zavascki AP. Severe infusion-related adverse events and renal failure in patients receiving high-dose intravenous Polymyxin B. Antimicrob Agents Chemother. 2018;62(1). doi:10.1128/AAC.01617-17
   Web of Science ®Google Scholar
• Elefritz JL, Bauer KA, Jones C, Mangino JE, Porter K, Murphy CV. Efficacy and safety of a colistin loading dose, high-dose maintenance regimen in critically ill patients with multidrug-resistant gram-negative pneumonia. J Intensive Care Med. 2017;32(8):487–493. doi:10.1177/0885066616646551
   PubMed Web of Science ®Google Scholar
• Katip W, Yoodee J, Uitrakul S, Oberdorfer P. Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae. Sci Rep. 2021;11(1):18. doi:10.1038/s41598-020-78098-4
   PubMed Web of Science ®Google Scholar
• Lakota EA, Landersdorfer CB, Nation RL, et al. Personalizing Polymyxin B dosing using an adaptive feedback control algorithm. Antimicrob Agents Chemother. 2018;62(7). doi:10.1128/AAC.00483-18
   Web of Science ®Google Scholar
• Temocin F, Erdinc S, Tulek N, Demirelli M, Bulut C, Ertem G. Incidence and risk factors for colistin-associated nephrotoxicity. Jpn J Infect Dis. 2015;68(4):318–320. doi:10.7883/yoken.JJID.2014.223
   PubMed Web of Science ®Google Scholar
• Katip W, Oberdorfer P. Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically ill patients infected with carbapenem-resistant Acinetobacter baumannii: a propensity score-matched analysis. Pharmaceutics. 2021;13(2). doi:10.3390/pharmaceutics13020162
   Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients: a propensity score-matched analysis. Antibiotics. 2020;9(10). doi:10.3390/antibiotics9100647
   Web of Science ®Google Scholar